PKM2 is a key enzyme involved in the metabolic reprogramming of cancer cells, and studies have indicated that apigenin can target the K433 site of PKM2, inhibit glycolysis and suppress the proliferation of CRC cells and tumor progression both in vitro and in vivo (Shi et al., 2023). This evidence concerns the gene PKM and neoplasm.